Tomahawk, WI 09/18/2014 (Basicsmedia) – The biotech space remains the only performing industry at a time when the world economy is on a downward-trend, according to CNBC’s Jim Cramer.  ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) remains a top pick for the ‘Mad Money’ analyst as a pioneer of antisense technology, which is expected to revolutionize the medical space going forward.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), according to Cramer remains the only ideal platform in the medical space that can be’ relied upon, for treating nasty genetic disorders with the antisense technology. The company also owns an impressive pipeline of drugs most of which are used to treat diseases in the medical space.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has also signed a number of deals with other pharmaceutical companies that continue to license it’s technology in the medical space. The pharmaceutical company has already partnered with Genzyme, a Sanofi SA (ADR) (NYSE:SNY) for the commercialization of its lead product Kynamro. The pharmaceutical company already has five drugs in phase 3 development that are expected to bolster it’s pipeline of drugs once approved it also has a dozen more drugs believed to be in phase 2 stage of development.

During an interview on CNBC, CEO, Stanley Crooke, reiterated that ISIS enjoys an advantage in the space, due to its wide connections with other pharmaceutical companies like AstraZeneca plc (ADR)(NYSE:AZN). The CEO also reiterated that the company has 32 drugs being developed by 400-people, backed by one of the best technologies in the industry.

“[…] We have a drug that we are very-very excited about that is just in clinical trials, and that’s an androgen receptor drug to treat androgen receptor-dependent prostate cancer. The beauty off course of our technology is we avoid the mechanisms of resistance that happens at the protean level, so we and AstraZeneca are very excited about that, “said Mr. Crooke.

The CEO also reiterated that after being in the industry for over 25 years, they were not contemplating about changing the company’s, despite sharing a name with a terrorist group in Syria.

“We’ve been ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) for 25 years and I don’t feel like I want to capitulate to these terrorist by changing my name, they can change their name,” said Mr. Crooke.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.